Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II metronomic oral idarubicin in intermediate-advanced hepatocellular carcinoma after sorafenib/regorafenib failure or intolerance
2017-003653-42Phase 2Terminated
- Sponsor
- Centro di Riferimento Oncologico di Aviano
- Start
- Sep 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idarubicin in hepatocellular carcinoma (HCC), sponsored by Centro di Riferimento Oncologico di Aviano. Primary endpoint: 6‑month overall survival. Started Sep 2021; status: terminated.
02
Drugs
idarubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2017-003653-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003653-42.